<qa>  What antibody was used to compare the CD105 levels at baseline and after treatment?II. To compare the soluble CD105 levels at baseline and after treatment between the group receiving bevacizumab alone and the group receiving bevacizumab in combination with anti-endoglin monoclonal antibody TRC105. 